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Objective: Human-embryonic-stem-cell (hESC) lines derived from chromosomally or genetically
abnormal embryos obtained following preimplantation genetic diagnosis are valuable in investigating
genetic disorders.
Materials and methods: In this study, a new hESC line, Center of Clinical Reproductive Medicine 8
(CCRM8) was established by isolation, culture, and passaging of the inner cell mass of mosaic trisomy 9
embryos.
Results: A karyotype analysis showed that the hESC line possessed a euploid (46 chromosomes). The
undifferentiated hESCs exhibited long-term proliferation capacity and expressed typical markers of
OCT4, TRA-1-60, and TRA-1-81. In vitro embryoid-body (EB) formation, differentiation, and in vivo
teratoma production conﬁrmed the pluripotency of the hESC line. The data represented here are the ﬁrst
detailed report on the characterization and differentiation of one Chinese hESC line generated from
mosaic trisomy 9 embryos.
Conclusion: Our study showed that chromosomally aberrant embryos could generate a normal hESC line,
which would be useful in investigating gene function and embryo development.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Human embryonic stem cells (hESCs) possess pluripotent po-
tentials for multidirectional differentiation in vivo and in vitro.
These cells remain as undifferentiated features and keep the pro-
liferative capacity during long-term in vitro culture, while main-
taining the normal diploid karyotype [1]. For these reasons, hESCs
are considered a superior model for studying embryogenesis, hu-
man development, control of gene expression, and etiopatho-
genesis of birth defects. In addition, these cells have been applied
for drug screening and developmental toxicity test, and used as aproductive Medicine, Center
Hospital, Nanjing Medical
_nj@126.com (J. Liu).
bstetrics & Gynecology. Publishedsource of cells for tissue replacement therapy in clinical settings
[2e4]. Today, hundreds of hESC lines are generated following the
establishment of the ﬁrst hESC line by Thomson et al in 1998 [1].
Normal hESCs are generally isolated from surplus, frozen em-
bryos donated by couples who have accepted in vitro fertilization
(IVF) treatments and have fulﬁlled their family plan [1,4]. Such
normal hESCs can satisfy the needs of most investigations when the
application of human embryos for research is restricted by ethics
concerns inmany countries [5]. It is noteworthy that hESCs carrying
genetic diseases have been successfully applied in studying the
relevant etiopathogenesis. Such hESCs are more attractive study
models that may face less ethics scrutiny. This is due to the fact that
they are derived from an abundant source of discarded embryos
that were readily diagnosed by preimplantation genetic screening
(PGS) and preimplantation genetic diagnosis (PGD) for having
chromosomal aberrations or carrying of genetic disorders [6]. PGDby Elsevier Taiwan LLC. All rights reserved.
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implantation of a fertilized egg carrying a serious genetic disease,
thus increasing the rate of successful IVF and advanced single-cell-
based technologies [7]. PGS was introduced into clinical practice for
screening and discarding aneuploid embryos, thus improving the
chance of healthy conceptions after an infertility treatment in pa-
tients with concerns of poor prognoses, such as advanced maternal
age, repeated implantation failure, and recurrent miscarriage [8,9].
Normal hESC lines have been generated from discarded em-
bryos (after PGS or PGD) obtained from IVF-embryo transfer or
intracytoplasmic sperm injection by conventional inner-cell-mass
isolation, culture, and passage [6,10e15]. Some of them were
derived from the embryos with chromosome inversion through
long- or short-arm repeat. To date, December 26, 2013, 243 hESC
lines were eligibly registered in the National Institutes of Health
Registration, including 69 hESC lines with disease-speciﬁc muta-
tions, with 18 out of 69 hESC lines going through PGD. It should be
pointed out that human stem cell lines from trisomy embryos,
including trisomy 5, trisomy 16 [16], trisomy 1 [17], and trisomy 13
[18], have been established. However, no hESC line derived from
trisomy 9 is currently available. Human chromosome 9 is highly
polymorphic, and pericentric inversions occur in more than 1% of
the pregnant population [19]. The frequent occurrence of in-
versions on human chromosome 9 can induce long arm and short
arm to duplicate repeats [19e21], resulting in mosaic trisomy 9.
This abnormal karyotype was reported as being related with many
types of diseases, such as increased abortion rate [22], male sterility
[23], and neonatal congenital malformation [24]. Thus, hESCs rep-
resenting mosaic trisomy 9 embryos would be useful for in vitro
studies of embryogenesis and gene function on chromosome 9.
Here, we established an hESC line, CCRM8, from a mosaic tri-
somy 9 embryo. We observed that CCRM8 grew in colony,
expressed stem cell markers, were capable of long-term prolifera-
tion, and possessed pluripotent differentiation potentials. It is
interesting that CCRM8 carried a normal karyotype of 46, XX. The
hESC line would be useful in investigating gene function on chro-
mosome 9 and the speciﬁc mechanism for euploid recovery.Materials and methods
Human embryos and ethics approval
Human mosaic trisomy 9 embryos employed in this study for
establishing hESCs were donated from couples that participated in
the IVF program for infertility treatment. The study was approved
(date of approval: October 13, 2008) by the local Institutional Re-
view Board of the First Afﬁliated Hospital, Nanjing Medical Uni-
versity. All voluntary couples enrolled into this study signed an
informed consent form.Fluorescence in situ hybridization
An embryo was ﬁxed at the positions of 2 and 4 o'clock with the
holding pipette of a micromanipulator system (Narishige, Tokyo,
Japan). The zona pellucida around the blastomere biopsy was ﬁred,
and one or two blastomeres were pumped out by negative pressure
using a blastomere biopsy needle. The blastomeres were washed
with phosphate-buffered saline (PBS) and placed in a hypotonic
solution (1% sodium acetate þ 6 mg/mL bovine serum albumin) for
5e10 minutes. Then, the blastomeres were transferred into the
ﬁxed liquid (0.01 mol/L hydrochloric acid þ 0.1% TWEEN 20) before
being moved to the hybrid zone on the glass slides coated with
polylysine. Small drops of the ﬁxed liquidwere added onto the glass
slides until the cytomembrane ruptured, and then rinsed with PBS.The blastomeres on the slides were dried in the air at room
temperature.
The blastomereswere put into 2 standard saline citrate (SSC) for
10 minutes; dehydrated in turn by 70% alcohol, 85% alcohol, and
absolute ethyl alcohol;anddriedat roomtemperature. Probemixture
(chromosome 9 centromeric probes; Vysis, Illinois, USA) was dena-
tured in 73C water bath for 5 minutes, then added onto the blasto-
meres on the slides. After mounting, the glass slides were put into a
humidiﬁed box overnight. The glass slides were washed by eluent
(0.4 SSC/0.3% Nonidet P40; Sigma, St. Louis, USA) at 70C for 2 mi-
nutes, then dried in the air. Afterward, the blastomeres were stained
with 40,6-diamidino-2-phenylindole, mounted, and photographed.
Preparation of the feeder layer
Mitomycin C-treated (MCT) mouse embryonic ﬁbroblasts
(MEFs) were used as a feeder layer to coculture hESCs. Pregnant
Institute of Cancer Research mice were purchased from the Model
Animal Research Center of Nanjing University, and embryos of 12.5
days old were isolated from the mice. Brieﬂy, the heads and all
viscera of the embryos were removed after the embryos were
separated from the uterus. The remaining embryos were minced
into pieces, digested with 0.25% trypsin/EDTA (Invitrogen, Wal-
tham, USA), and incubated in Dulbecco's modiﬁed Eagle's medium
(Invitrogen, Waltham, USA) plus 10% fetal bovine serum (Invi-
trogen, Waltham, USA) at 37C with 5% CO2. MEFs at passages 2e5
were inactivatedwith 10 mg/mLmitomycin C (Roche, Basel, USA) for
2.5e3 hours. The cells were collected following digestion with
0.05% trypsin/EDTA, counted, and plated onto 0.1% gelatin-coated
(Invitrogen) dish or plate with a density of 2.5  104/cm2.
Generation of hESCs
The zona pellucida of the blastocyst was removed by 0.1%
Tyrode's solution (SAGE, New York, USA) on Day 5 or 6 of
embryogenesis. Then, the whole zona-free blastocyst was plated
onto MCTeMEFs and cultured in hESC medium, which was
composed of Dulbecco's modiﬁed Eagle's medium/F12, 20%
Knockout Serum, 1% glutamine, 1% nonessential amino acids,
0.1mM 2-mercaptoethanol, 1% penicillinestreptomycin (all pur-
chased from Invitrogen), and 10 ng/mL basic ﬁbroblast growth
factor (bFGF; PeproTech, USA) at 37C with 5% CO2 and 20% O2. The
medium was changed daily. After 5e7 days, ﬂat, colony-like cell
masses appeared. They were plated onto fresh MCTeMEFs after
mechanically dissociated into small pieces. For later passages, hESCs
were expanded mechanically (before passage 5), or digested (pas-
sage 6 afterward) for 10 minutes with 1 mg/mL collagenase IV
(Invitrogen), and then plated onto freshMCTeMEFs every 5e7 days.
Karyotype analysis
The standard G-band chromosome analysis and the array-based
comparative genomic hybridization were performed according to
the manufacturer's protocols.
Alkaline-phosphatase staining
The Alkaline Phosphatase Detection Kit (Vector Laboratories,
Burlingame, USA)was selected to carry out the alkaline phosphatase
(AKP) staining of hESCs according to the manufacturer's protocol.
Immunostaining of hESCs
The primary antibodies of anti-Oct-3/4, anti-SSEA4, anti-Tra-1-
60, and anti-Tra-1-81 (all from Chemicon, Salem, USA) were used
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ﬁxed with 4% paraformaldehyde (Sigma, USA) at room temperature
for 10 minutes, permeated with 0.1% Triton X-100 (Sigma, St. Louis,
USA)/PBS on ice for 10 minutes, and blocked with fresh 2% bovine
serum albumin (Sigma)/PBS at room temperature for 30 minutes.
The treated hESCs were washed with PBS for 5 minutes, and then
incubated with primary antibodies overnight at 4C. After the 5-
minute rinse with PBS, the hESCs were stained with Cy2-
conjugated or ﬂuorescein-isothiocyanate-conjugated secondary
antibodies (Jackson ImmunoResearch, West Grove, PA, USA) in the
dark for 30 minutes. The stained hESCs were mounted with 40,6-
diamidino-2-phenylindole (Vector Laboratories) after being
washed with PBS for 5 minutes, and photographed under a ﬂuo-
rescence microscope (Tokyo, Nikon, Japan).Reverse transcriptionepolymerase chain reaction
The harvested cells were washed with PBS, and RNA was
extracted with TRIzol reagents (Invitrogen, Waltham, USA). Com-
plementary DNAs were synthesized by reverse transcription using
a reverse-transcription kit (Takara, Shiga, Japan) according to the
manufacturer's protocol. Polymerase chain reaction (PCR) was
carried out in 50 mL volume reactions containing 5 mL of 10 PCR
buffer, 4 mL of 2.5mM deoxyribonucleotide triphosphates, 1 mL of
each primer (10mM), 0.5 mL of Taq enzyme (5 U/mL), 8 mL of com-
plementary DNA template, and 31.5 mL of ultrapure water. The
reverse transcriptionePCR conditions were as follows: pre-
denaturing at 94C for 2 minutes, denaturing at 94C for 45 sec-
onds, annealing at 55C for 45 seconds, and elongation at 72C for
45 seconds. Following 30 cycles of ampliﬁcation, ﬁnal elongation
was performed at 72C for 5 minutes. The primer sequences are
shown in Table 1. The PCR products were resolved by agarose gel
electrophoresis, and the DNA bands were visualized by ethidium-
bromide staining and observed under an ultraviolet automatic
image analyzer.Embryoid body and teratoma formation
Following 5e7 days of culture, hESC colonies were suspended
with collagenase IV and dispase. For the formation of EBs, cell
clusters were plated onto bacteria-culture dishes and allowed to
culture for 1e2 weeks in embryonic-stemmedia without bFGF and
feeder. For teratoma formation, 5  106 to 10  106 hESCs were
injected intramuscularly into mice with severe combined immuno-
deﬁciency disease. After 2e3 months, the mice were sacriﬁced and
teratoma tissues were dissected into sections, and then ﬁxed in 4%
paraformaldehyde. The sections from the ﬁxed teratoma tissues
were stained with hematoxylin and eosin, and photographed.Table 1
Designations, sequences, and the sizes of reverse transcriptionepolymerase chain
reaction amplicons.
Name Sequence from 50-30 Size (bp)
AFP forward AGCTTGGTGGTGGATGAAAC 182
AFP reverse TCTGCAATGACAGCCTCAAG
BMP4 forward AAGCGTAGCCCTAAGCATCA 197
BMP4 reverse ATGGCATGGTTGGTTGAGTT
Nestin forward GCAGCACTCTTAACTTACGATC 176
Nestin reverse CTGACTTAGCCTATGAGATGGA
GAPDH forward GAAGGTCGGAGTCAACGGATTT 223
GAPDH reverse CTGGAAGATGGTGATGGGATTTC
GAPDH ¼ glyceraldehyde-3-phosphate dehydrogenase; AFP ¼ alpha fetoprotein;
BMP4 ¼ Bone Morphogenetic Protein 4.Results
Characterization of mosaic trisomy 9 embryos
During the IVF treatment, the chromosome-abnormality cou-
ples go through a preimplantation diagnosis by ﬂuorescence in situ
hybridization (FISH) to choose a normal karyotype embryo for
transplantation, and, generally, abnormal embryos are discarded. In
some cases, infertile couples voluntarily donated embryos with
abnormal signals for hESC research. In our study, the donation
couple obtained 20 ovules after egg retrieval in a menstrual cycle,
and 16 of them were fertilized after intracytoplasmic sperm in-
jection. Eight embryos grew to the eight-cell stage. We found two
normal and six abnormal embryos, of which one embryo showed
mosaic trisomy 9 karyotype (Table 2). The short-arm repeat on
trisomy 9 was conﬁrmed by PGD, in which a single blastomere of
the eight-cell stage of the embryo was sucked out (Figure 1AeD)
and subjected to FISH assay (Figure 1EeH). The FISH results clearly
showed that a single blastomere biopsy expressed two red spots
(Figure 1F) and three green spots (Figure 1G), which meant chro-
mosome 9 short-arm terminal repeat.
Derivation and characterization of hESC line
The whole zona-free blastocysts from chromosome 9 short-arm
terminal repeat embryo were plated ontoMCTeMEFs, and cultured
in an hESC medium after being removed from the zona pellucida in
Tyrode's solution. After 5e7 days, the appearing ﬂat, colony-like
masses were subcultured through mechanical scraping into small
pieces. At last, one independent stable hESC line, CCRM8, was
successfully established by mechanical (before the 5th generation)
and enzymatical (after 6th generation) passage and expansion.
During culture, the hESCs grew as ﬂat colonies with clear cell
boundaries (Figures 2E and 3B), and large nuclei and clear nucleoli
presented in growing hESCs, giving a high nucleoplasmic ratio. We
observed that the hESCs proliferated fast during Days 5e6, and
should be subcultured on Days 6e7; otherwise, the hESCs would
begin to spontaneously differentiate. After AKP staining, the hESC
colonies turned into violet blue, indicating the strong expression of
AKP (Figure 3C). Furthermore, expressions of the stem-cell markers
TRA-1-60, TRA-1-81, and OCT4 were detected in the hESCs
(Figure 3DeF). Interestingly, CCRM8 carried a normal diploid kar-
yotype of 46, XX (Figure 3A), although it derived from the embryo
with chromosome 9 short-arm terminal repeat. In our study,
CCRM8 cells could maintain the hESCs' distinctions even if they
were cultured to the 50th generation. Thus, CCRM8 was a typical
hESC line, capable of self-renewal, expression of stem-cell markers,
and long-term culture.
Differentiation of hESCs
The hESCs exhibited their pluripotency when they spontane-
ously differentiated into morphologically distinct cell types repre-
senting all the three embryonic germ layers in vitro and in vivo. We
found that EBs were formed when CCRM8 cells were cultured in an
ultralow-attachment dish without bFGF and feeder layer. The EBs
grew and differentiated gradually, and cyst-shaped EBs were pre-
sented on Day 7 (Figure 4A). Moreover, the reverse tran-
scriptionePCR results showed expression of early differentiation
markers, including nestin (ectoderm), Bone Morphogenetic Protein
4 (BMP4) (mesoderm), and alpha fetoprotein (AFP) (endoderm) in
EBs on Day 7 (Figure 4B), indicating CCRM8 in vitro could differ-
entiate into the three germ layers. Subsequently, the in vivo plu-
ripotency of hESCs was accessed by teratoma-formation
experiments. We observed a lump at the injection site after the
Table 2
Clinical data of the donor couple.
Female Male Embryos
Age Karyotype Age Karyotype No. of embryos FISH signals
28 46, XX, inv(9) (q11;q22) 29 46, XY 3 2 Red, 0 green
5 2 Red, 0 green
7 0 Red, 0 green
8 0 Red, 3 green
9 0 Red, 0 green
10 2 Red, 2 green
11 2 Red, 2 green
15 2 Red, 0 green
“Red” represents long-arm terminal; “green” represents short-arm terminal. The “2 red and 2 green”means normal embryos; the “3 green”means mosaic trisomy 9 embryos
(short-arm repeat).
FISH ¼ ﬂuorescence in situ hybridization.
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bined immunodeﬁciency disease at 8e12 weeks of postinjection
(Figure 4C). The gross-anatomy analysis indicated that the lump
indeed came from injected hESCs rather than intrinsic tumori-
genesis based on the absence of peplos or the destruction in lump-
surrounding tissues. Hematoxylin and eosin staining analysis
conﬁrmed that nerve cells (ectoderm lineage, Figure 4D), glandFigure 1. Identiﬁed chromosome 9 short-arm repeat by ﬂuorescence in situ hybridization
embryo. (E) The blastomere nucleus was indicated by 40 ,6-diamidino-2-phenylindole stai
FISH showed chromosome 9 short-arm repeat (three green dots). (H) Picture merged from
Figure 2. Morphology of zygotes and human-embryonic-stem-cell colony. (A) The embryo
(D) the whole embryo after zona removal; and (E) human-embryonic-stem-cell colony at p(endoderm lineage, Figure 4E), and cartilage (mesoderm lineage,
Figure 4F) were present in the retina and choroid plexus. These data
indicated that the injected hESCs could develop into all three germ
layers in derived teratoma, conﬁrming the hESC pluripotency
in vivo. In summary, although established from a mosaic trisomy 9
embryo, CCRM8 was characterized as normal hESC, in that it not
only maintained hESC-like morphology and expressed stem-cell(FISH). (AeD) A single blastomere was sucked out after laser drilling on an eight-cell
ning. (F) FISH showed chromosome 9 long-arm terminal normal (two red dots). (G)
(EeG).
at eight-cell stage; (B) the embryo at morula stage; (C) the embryo at blastocyst stage;
assage 2. (Scale bar: 10 mm).
Figure 3. Characterization of CCRM8 by karyotype and immunohistochemistry analysis. (A) Karyotype analysis of CCRM8 by array-based comparative genomic hybridization;
normal 46, XX was observed. (B) Human-embryonic-stem-cell (hESC) clones at passage 17 under a phase-contrast microscope. Scale bar: 10 mm. (C) The hESCs were determined by
alkaline-phosphatase staining. Scale bar: 10 mm. (DeF) and (def) Detection of stem-cell markers expressed in hESCs. The nuclei were stained by 40 ,6-diamidino-2-phenylindole
staining. (D) and (d) TRA-1-60. (E) and (e) TRA-1-81. (F) and (f) OCT4. (DeF) 4 magniﬁcation. (def) 20 magniﬁcation. CCRM8 ¼ Center of Clinical Reproductive Medicine 8.
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and in vivo.
Discussion
In our study, one new hESC line, CCRM8, was generated from
PGD-discarded embryo donated by a Chinese couple. Several
studies have shown that hESC lines can be derived from abnormal
embryos donated following PGD [25,26]. Such hESC lines can be
useful models for studying genetic anomaly in relevant diseases.
The CCRM8 cell line was established from an embryo diagnosed as
mosaic trisomy 9. However, karyotypic analyses at an early stage
(P17) showed the cell line was of normal karyotype (46, XX). Pre-
vious investigators have reported that both normal and abnormal
hESC lines were successfully derived from PGD-diagnosed aneu-
ploid embryos [16,27]. There are also studies that demonstrated the
successful establishment of normal pluripotent hESC lines from
both monosomic and trisomic embryos [28e30], indicating that,
just like natural embryonic development in vivo, extensive genetic
alterations and selection could occur under in vitro culture condi-
tions. In our case, the normal karyotype, CCRM8, is derived from an
embryo diagnosed as mosaic trisomy. However, we could notcompletely exclude the possibility of new mutations, and the cells
with normal karyotype most likely arose from the normal cells
without trisomy defects. Presumably, the normal cells enjoyed a
proliferation or survival advantage over the trisomic cells, leading
to selective expansion in the culture. This transformation may
contribute to the state of mosaicism and rapid growth of the stem
cells with normal karyotype [31]. In spite of the mechanism, from a
practical point of view, such possibility pointed to a feasible
approach with which normal cell cultures can be obtained from
mosaic (discarded) embryos that are relatively easy to obtain in a
clinical setting.
Alternatively, the hESCs with normal karyotype may come from
trisomic cells. In this case, we have to assume that the trisomic stem
cells have a self-correction capability, which enables them to revert
back to chromosomally normal cells either partially or completely.
Indeed, it has been reported that aneuploidymammalian hESCs can
instinctively revert to diploid cells. The hESCs derived from tri-
pronuclear embryos with or without extra-pronuclear removal
spontaneously recover to diploid karyotype in a long-term culture
[32]. Additionally, haploid ESCs can also spontaneously transfer to
diploid karyotype during culture [33]. Thus, mosaic trisomy 9 hESCs
have a chance to transform back to chromosomally normal cells
Figure 4. Differentiation of CCRM8 cells in vitro and in vivo. (A) and (B) Human-embryonic-stem-cell (hESC) differentiation in vitro. (A) Embryoid bodies at differentiation, day 7.
Scale bar: 100 mm. (B) Three germ-layer markers expressed in embryoid bodies as detected by reverse transcriptionepolymerase chain reaction. Lane 1, glyceraldehyde-3-phosphate
dehydrogenase as control. Lane 2, mesoderm marker BMP4. Lane 3, ectoderm marker, nestin. Lane 4, endoderm marker, AFP. (CeF) The hESCs differentiated in vivo. (C) Teratomas
(asterisk) were formed after hESCs injected into mice with severe combined immunodeﬁciency disease for 2e3 months. Nerve cells (D, arrow), gland (E, arrow), and cartilage
(F, arrow) were indicated by hematoxylin and eosin staining of teratoma sections. (DeF) Scale bar: 50 mm. GAPDH ¼ glyceraldehyde-3-phosphate dehydrogenase; AFP ¼ alpha
fetoprotein; BMP4 ¼ Bone Morphogenetic Protein 4; CCRM8 ¼ Center of Clinical Reproductive Medicine 8.
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study, along with others [34], the karyotype analysis was not per-
formed at the initial passages, leaving the possibilities of mosaicism
and instinctive reversion unsolved.
It has been reported that mosaic blastomeres are frequently
found in early-stage embryos [33,35], and the self-correction phe-
nomenon may also happen in the embryo stage. The heterogeneity
may result in false-positive or false-negative artifact of PGD test.
Therefore, it can be speculated that the normal karyotype of CCRM8
was possibly due to one of the aforementioned possibilities.
Although the karyotypes of hESC lines derived from trisomy 9
embryos appeared normal, we could not eliminate the possibility of
newmutations in the cell line. Once again, suchmutations reversed
the cell karyotype, and at the same time, might lead to increased
survival capability, thus enabling their dominance under the in vitro
culture conditions. This possibility would be cleared if more precise
experiments, such as second-generation sequencing, were applied.
Thus, further characterization is needed to obtain a complete pic-
ture of the genetic background of the new cell line.
Despite of the aforementioned uncertainty, here, we ﬁrst report
the successful derivation of an hESC line, CCRM8, from a mosaic
trisomy 9 embryo donated by a Chinese couple. The hESC line
exhibited all the key characteristics of hESCs, demonstrating that
the PGD procedure does not affect the characteristics anddifferentiation potential of hESCs. Now, the cell line is available for
distribution to the stem-cell research community, which will
facilitate embryonic stem-cell research.
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